Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
0 hedge funds and large institutions have $0 invested in Audentes Therapeutics, Inc in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 186 closing their positions.
100% less funds holding
Funds holding: 188 → 0 (-188)
100% less funds holding in top 10
Funds holding in top 10: 19 → 0 (-19)
100% less capital invested
Capital invested by funds: $2.57B → $0 (-$2.57B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 186
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$220M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$193M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$95.4M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$87.1M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$81.3M |
BOLD Hedge Fund Activity: Q1 2020 in Review
0 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2020, worth a combined $0 — down 100% from $2.57B a quarter earlier.
Sellers outnumbered buyers: 186 funds closed out of BOLD and 0 opened new positions — a net loss of 186 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $220M sold.
- 0 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2020, down from 188 in Q4 2019.
- Funds reported $0 of Audentes Therapeutics, Inc stock for Q1 2020, down 100% quarter-over-quarter.
- 0 funds opened new Audentes Therapeutics, Inc positions in Q1 2020 and 186 closed out, a net change of -186 holders.
- The largest Audentes Therapeutics, Inc seller in Q1 2020 was BlackRock, an estimated $220M sold.
Based on aggregated 13F filings for Q1 2020.